Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – Time to Sell?

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)’s share price gapped down prior to trading on Friday . The stock had previously closed at $8.80, but opened at $8.54. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.5250, with a volume of 16,131 shares changing hands.

Shionogi & Co., Ltd. Unsponsored ADR Stock Down 3.1%

The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.13 and a current ratio of 6.63. The company has a market capitalization of $14.51 billion, a PE ratio of 13.33, a price-to-earnings-growth ratio of 2.05 and a beta of 0.20. The firm’s 50-day simple moving average is $8.43 and its 200 day simple moving average is $8.50.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last announced its quarterly earnings results on Monday, October 27th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.02. The business had revenue of $740.85 million during the quarter, compared to the consensus estimate of $742.35 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 39.53% and a return on equity of 12.25%. As a group, equities research analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 earnings per share for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.